Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion.

Literature DB >> 16424543

Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion.

T Y Y Lai, G K Y Lee, W-M Chan, D S C Lam.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Siderophores
Deferoxamine

Year: 2006 PMID： 16424543 PMCID： PMC1860174 DOI： 10.1136/bjo.2005.080119

Source DB: PubMed Journal: Br J Ophthalmol ISSN： 0007-1161 Impact factor: 4.638

× No keyword cloud information.

9 in total

1. Bull's eye maculopathy with deferoxamine.

Authors: V Bansal; I Elgarbly; F D Ghanchi; P L Atkinson
Journal: Eur J Haematol Date: 2003-06 Impact factor: 2.997

2. Bilateral vitelliform maculopathy and deferoxamine toxicity.

Authors: Christine R Gonzales; Albert P Lin; Robert E Engstrom; Allan E Kreiger
Journal: Retina Date: 2004-06 Impact factor: 4.256

3. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings.

Authors: A H Rahi; J L Hungerford; A I Ahmed
Journal: Br J Ophthalmol Date: 1986-05 Impact factor: 4.638

4. Ocular changes in patients undergoing long-term desferrioxamine treatment.

Authors: G B Arden; B Wonke; C Kennedy; E R Huehns
Journal: Br J Ophthalmol Date: 1984-12 Impact factor: 4.638

5. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.

Authors: B A Davis; J B Porter
Journal: Blood Date: 2000-02-15 Impact factor: 22.113

6. The expanded clinical spectrum of deferoxamine retinopathy.

Authors: Robert Haimovici; Donald J D'Amico; Evangelos S Gragoudas; Samuel Sokol
Journal: Ophthalmology Date: 2002-01 Impact factor: 12.079

7. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.

Authors: J B Porter; M S Jaswon; E R Huehns; C A East; J W Hazell
Journal: Br J Haematol Date: 1989-11 Impact factor: 6.998

8. Desferrioxamine related maculopathy: a case report.

Authors: Anita Arora; Siobhan Wren; Kevin Gregory Evans
Journal: Am J Hematol Date: 2004-08 Impact factor: 10.047

9. Ocular toxicity of high-dose intravenous desferrioxamine.

Authors: S C Davies; R E Marcus; J L Hungerford; M H Miller; G B Arden; E R Huehns
Journal: Lancet Date: 1983-07-23 Impact factor: 79.321

9 in total

7 in total

1. Neuroprotection of brain-permeable iron chelator VK-28 against intracerebral hemorrhage in mice.

Authors: Qian Li; Jieru Wan; Xi Lan; Xiaoning Han; Zhongyu Wang; Jian Wang
Journal: J Cereb Blood Flow Metab Date: 2017-05-23 Impact factor: 6.200

2. Desferrioxamine-related ocular toxicity: a case report.

Authors: Sumu Simon; Paul A Athanasiov; Rajeev Jain; Grant Raymond; Jagjit S Gilhotra
Journal: Indian J Ophthalmol Date: 2012-07 Impact factor: 1.848

3. Contrast sensitivity in patients with Beta-thalassemia major and sickle cell disease under regular transfusions and treatment with desferrioxamine.

Authors: Spyridon Gorezis; Ioannis Asproudis; Nikolaos Chalasios; Aikaterini Karali; Elena Tsanou; Dimitrios Peschos; Aikaterini Christodoulou; Miltiadis Aspiotis
Journal: Open Ophthalmol J Date: 2010-07-29